Lu-177-PSMA Therapy Eligibility Planner
An evidence-gated eligibility and sequencing aid for PSMA radioligand therapy in mCRPC
High-yield mode — key points, high-yield facts, tables & quizzes only. Toggle off for full text.
Enter the patient's disease state, prior therapies, PSMA-PET result, and organ function to see whether ¹⁷⁷Lu-PSMA-617 is supported by the current evidence, with the reasoning and grade-cited trials behind each answer. Fields act as gates (PSMA positivity, mCRPC status, and organ function must be satisfied) before line-of-therapy logic applies. This states what the published evidence supports for a population — it is a proposal for discussion, not a written directive.
Recommendation
—
Encodes the population-level evidence (VISION, PSMAfore, TheraP) and label requirements. It does not replace multidisciplinary judgement, dosimetry, or a written directive. Confirm the current approved indication and funding at time of use — the label has moved.
Evidence & sources
AVISION — Sartor O, et al. N Engl J Med 2021: OS benefit in PSMA-positive mCRPC after ARPI and taxane (the original indication).
APSMAfore — Morris MJ, et al.: benefit in taxane-naïve mCRPC after ARPI, supporting the 2025 pre-chemotherapy label expansion.
ATheraP — Hofman MS, et al. Lancet 2021: ¹⁷⁷Lu-PSMA-617 vs cabazitaxel — informs the Lu-PSMA-vs-taxane choice in taxane-eligible patients.
BFDG/PSMA discordance — Buteau JP, et al. Lancet Oncol 2022 (TheraP substudy): high FDG / low PSMA disease predicts poorer benefit.
BFDA prescribing information — lutetium Lu-177 vipivotide tetraxetan: PSMA positivity, mCRPC status, and organ-function requirements.